Full-Time

Specialty Account Manager

Migraine

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for central nervous system disorders

Biotechnology
Healthcare

Compensation Overview

$100k - $150kAnnually

+ Annual Bonus + Equity

Senior

San Diego, CA, USA

Must live in the territory's geography.

Category
Field Sales
Sales & Account Management

You match the following Axsome Therapeutics Inc's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree from an accredited college or university
  • Minimum of 5 years of field customer experience and/or account management
  • Minimum of 3 years Healthcare Professional experience with relevant CNS experience
  • 5 years of consistent top performance in the pharmaceutical, biotech or medical sales space
  • Demonstrated experience delivering outstanding results
  • Must live in the territory's geography
  • Proven ability to successfully manage multiple tasks concurrently under aggressive timelines in a dynamic environment
  • Comfortability with uncertainty and high expectations
  • Strong interpersonal, presentation, and communication skills
Responsibilities
  • Proficient in both virtual and live customer engagements
  • Develop a comprehensive and effective territory business plan aimed at achieving and exceeding quarterly & annual goals established by commercial leadership
  • Promote within our approved labeling in a comprehensive, fair, and ethical manner that is consistent with industry specific and corporate legal and regulatory guidelines
  • Develop strong customer relationships by better understanding the customer’s needs
  • Serve as a resource/consultant to customers and staff regarding payer policies and processes (i.e., eligibility and benefit verification, prior-authorization, and appeals/denials)
  • Maximize use of marketing resources to maintain and develop customer relationships for the purpose of growing the customers’ confidence to prescribe Axsome medications for appropriate patients
  • Communicate territory activity in an accurate and timely manner as directed by management
  • Provide feedback to sales and commercial leadership, colleagues, marketing, and other internal departments about changing environment and results
  • Successfully complete all training classes in a timely manner
  • Complete administrative duties in an accurate and timely fashion
  • Manage efforts within assigned promotional budget
  • Effectively collaborate across all corporate functions
  • Attend medical congresses and society meetings as needed
  • Ensure timely access for patients through patient services and savings programs
  • Overnight travel as indicated by the needs of the business
  • Additional responsibilities as assigned
Desired Qualifications
  • Migraine/CNS experience strongly preferred
  • Launch experience strongly preferred
  • Patient support services experience a plus
  • Strong digital marketing aptitude
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Size

201-500

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
  • Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
  • Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

What critics are saying

  • Increased competition from companies like Compass Pathways in the CNS market.
  • Potential delays in AXS-07 launch amid growing market anticipation.
  • Departure of key personnel like Lori Englebert may impact strategic direction.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders with limited current treatment options.
  • AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 4th, 2024
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 2nd, 2024
PDT Partners LLC Makes New $1.05 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

PDT Partners LLC makes new $1.05 million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Nov 29th, 2024
FORA Capital LLC Makes New $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

FORA Capital LLC makes new $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Nov 28th, 2024
Intech Investment Management LLC Makes New $983,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Intech Investment Management LLC makes new $983,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

Investing.com
Sep 27th, 2024
Wall Street SWOT: Axsome stock fortified by robust IP and CNS market potential

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has emerged as a prominent player in the biopharmaceutical industry, focusing on developing novel therapies for central nervous system (CNS) disorders.

MarketBeat
Aug 1st, 2024
Castleark Management LLC Invests $2.57 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Castleark Management LLC invests $2.57 million in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

Yahoo Finance
Jul 30th, 2024
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

Stock Titan
Jun 26th, 2024
Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Lori brings multifaceted experience in global pharmaceuticals and joins from Axsome Therapeutics, where she spent nearly five years as a member of the executive team serving as head of commercial and business development and most recently as head of product strategy.